Moleculin Biotech, Inc. (MBRX) - Dilution Analysis

10-Q filing | 5.3M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 6,367,956 shares of common stock upon the exercise of certain warrants with an exercise price of $2.3976 per share.

10-K filing | 3.2M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 49,498,576 → 2,070,000

10-Q filing | 49.5M shares outstanding

S-3 filing: This S-3 filing from Moleculin Biotech, Inc. relates to the resale of up to 64,864,864 shares of common stock by selling stockholders upon the exercise of warrants with an exercise price of $0.55 per share.

10-Q filing | 30.2M shares outstanding

8-K filing: Moleculin Biotech, Inc. closed a public offering of common stock, pre-funded warrants, and Series E warrants on June 23, 2025, with gross proceeds of approximately $5.9 million before deducting fees. ($5.9M proceeds)

S-1/A filing: The company is offering common stock, pre-funded warrants, and Series E warrants on a reasonable best efforts basis.

S-1/A filing: The company is filing an S-1/A to register the offering of common stock, pre-funded warrants, and Series E warrants.

S-1/A filing: The company is offering common stock, Series E warrants, and pre-funded warrants.

S-1 filing: The company is offering up to 10,989,010 shares of common stock together with warrants, pre-funded warrants to purchase up to 10,989,010 shares of common stock, and Series E warrants to purchase up to 21,978,020 shares of common stock.

10-Q filing | 14.1M shares outstanding

S-1 filing: This S-1 filing covers the offer and resale by the selling stockholder of up to 18,199,198 shares of common stock consisting of shares issuable upon exercise of Series D and Inducement Warrants.

10-K filing | 3.4M shares outstanding

8-K filing: Moleculin Biotech, Inc. entered into a Securities Purchase Agreement for the sale of 1,150,000 shares of common stock and pre-funded warrants to purchase 2,121,029 shares, along with unregistered warrants to purchase up to 6,542,058 shares of common stock in a private placement, with the closing occurring on February 26, 2025. ($10.5M proceeds)

RW filing: The company has determined not to proceed with the planned offering and confirms that no securities were sold in connection with the offering.

8-K filing: Moleculin Biotech, Inc. entered into a warrant exercise inducement offer letter with a holder of existing warrants to purchase up to 5,828,570 shares of common stock, reducing the exercise price to $1.00 per share, and agreed to issue inducement warrants to purchase up to 11,657,140 shares of common stock. ($5.8M proceeds)

S-1/A filing: Moleculin Biotech, Inc. is offering up to 23,809,524 shares of common stock at $0.84 per share along with Series C and Series D common warrants, and pre-funded warrants to certain purchasers, to advance Annamycin and other drug portfolios through clinical development and for working capital.

8-K filing: Moleculin Biotech, Inc. entered into a waiver and consent agreement with an investor to reduce the exercise price of warrants to purchase 5,828,570 shares of common stock and pay a cash fee of $750,000.

S-1/A filing: This S-1/A filing is for offering up to 23,809,524 shares of common stock, pre-funded warrants, Series C warrants, and Series D warrants. The offering is expected to terminate on February 18, 2025, and the net proceeds are estimated to be approximately $18.4 million.

S-1/A filing: This is an S-1/A filing for a combination offering of common stock and warrants.

S-1 filing: Moleculin Biotech is offering shares of common stock, together with Series C warrants and Series D warrants to purchase shares of common stock and pre-funded warrants to purchase shares of common stock.

POS AM filing: This is a POS AM filing for shares of common stock offered by selling shareholders, up to 939,316 shares issuable upon exercise of Common Warrants.

10-Q filing | 3.0M shares outstanding

8-K filing: Moleculin Biotech, Inc. entered into a Securities Purchase Agreement with an institutional investor for the sale of shares of common stock, pre-funded warrants, Series A Warrants, and Series B Warrants, with the closing expected on August 19, 2024. ($5.5M proceeds)

S-1/A filing: The filing is for an offering of common stock, Series A warrants, Series B warrants and pre-funded warrants.

S-1/A filing: The filing is an S-1/A form indicating the company is offering up to 2,978,723 shares of common stock, together with Series A and Series B warrants, pre-funded warrants and placement agent warrants.

10-Q filing | 2.5M shares outstanding

S-1/A filing: The filing is for an offering of shares of common stock, pre-funded warrants, and common warrants.

S-1 filing: The filing is an S-1 form for an offering of common stock, pre-funded warrants, and common warrants.

S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $200,000,000 of common stock, preferred stock, debt securities, warrants or units of securities.

10-Q filing | 2.5M shares outstanding

10-K filing | 2.2M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 29,810,443 → 2

S-1 filing: This S-1 filing pertains to shares of common stock offered by selling shareholders, up to 14,089,672 shares issuable upon exercise of Common Warrants, with 29,810,443 shares outstanding before the offering.

8-K filing: Moleculin Biotech, Inc. entered into Securities Purchase Agreements with investors for the sale of 3,602,253 shares of common stock and pre-funded warrants to purchase 3,442,583 shares, along with unregistered warrants to purchase up to 14,089,672 shares of common stock, in a registered direct offering and concurrent private placement, with gross proceeds expected to be approximately $4.5 million. ($4.5M proceeds)

10-Q filing | 29.8M shares outstanding

10-Q filing | 29.7M shares outstanding

10-Q filing | 28.7M shares outstanding

10-K filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

10-K filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

8-K filing: Moleculin Biotech, Inc. entered into an At Market Issuance Sales Agreement with Oppenheimer & Co. Inc. to sell shares of common stock with an aggregate sales price of up to $50.0 million and a purchase agreement with Lincoln Park Capital Fund, LLC for up to $20.0 million of shares of common stock.

S-3 filing: The company is filing an S-3 to register an indeterminate number of shares of Common Stock and Preferred Stock, such indeterminate principal amount of Debt Securities, such indeterminate number of Warrants to purchase Common Stock, Preferred Stock or Debt Securities, and such indeterminate number of units consisting of such securities up to $200,000,000.

10-Q filing | 28.4M shares outstanding

10-K filing | 11.5M shares outstanding

8-K filing: The underwriters exercised their option to purchase an additional 2,141,052 shares of common stock at $4.75 per share, resulting in gross proceeds of approximately $78.0 million. ($10.17M proceeds)

10-Q filing | 61.8M shares outstanding

10-Q filing | 61.7M shares outstanding

10-Q filing | 60.4M shares outstanding

S-3/A filing: This is an S-3/A filing for a shelf registration to offer up to $75,000,000 aggregate dollar amount of common stock, preferred stock, debt securities, warrants or units of securities from time to time.

10-K filing | 53.2M shares outstanding

8-K filing: Moleculin Biotech, Inc. entered into subscription agreements with institutional investors for the sale of up to 7,500,000 shares of common stock and warrants to purchase 5,625,000 shares at a combined price of $0.80 per share and warrant. ($6.0M proceeds)

S-3 filing: This is an S-3 filing for a shelf offering to issue up to $75,000,000 aggregate dollar amount of common stock, preferred stock, debt securities, warrants or units of securities from time to time.

S-3/A filing: This is an S-3/A filing for a shelf offering of up to $75,000,000 of common stock, preferred stock, debt securities, warrants or units of securities.